CCLA Investment Management Sells 13,213 Shares of Zoetis Inc. $ZTS

CCLA Investment Management reduced its stake in Zoetis Inc. (NYSE:ZTS) by 1.5% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 885,388 shares of the company’s stock after selling 13,213 shares during the period. CCLA Investment Management owned approximately 0.20% of Zoetis worth $111,390,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also made changes to their positions in the company. Halbert Hargrove Global Advisors LLC grew its position in Zoetis by 496.6% during the 3rd quarter. Halbert Hargrove Global Advisors LLC now owns 173 shares of the company’s stock worth $25,000 after acquiring an additional 144 shares during the last quarter. Global Wealth Strategies & Associates acquired a new position in Zoetis during the 4th quarter worth $25,000. Lodestone Wealth Management LLC acquired a new position in Zoetis during the 4th quarter valued at about $30,000. KERR FINANCIAL PLANNING Corp acquired a new position in Zoetis during the 3rd quarter valued at about $31,000. Finally, Holos Integrated Wealth LLC bought a new position in shares of Zoetis in the 4th quarter worth $32,000. Institutional investors own 92.80% of the company’s stock.

Analysts Set New Price Targets

A number of analysts recently weighed in on the stock. Leerink Partners reiterated a “market perform” rating on shares of Zoetis in a research report on Tuesday, March 10th. Piper Sandler reiterated a “neutral” rating and issued a $135.00 price target (down from $190.00) on shares of Zoetis in a research report on Thursday, January 22nd. The Goldman Sachs Group upgraded shares of Zoetis to a “buy” rating in a research report on Monday, December 15th. Weiss Ratings downgraded shares of Zoetis from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Friday, March 27th. Finally, UBS Group set a $136.00 price target on shares of Zoetis in a research report on Thursday, January 29th. Six analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $152.91.

Zoetis Stock Performance

Shares of ZTS stock opened at $119.66 on Thursday. The company has a debt-to-equity ratio of 2.71, a quick ratio of 1.94 and a current ratio of 3.03. The company has a market capitalization of $50.51 billion, a P/E ratio of 19.88, a price-to-earnings-growth ratio of 1.80 and a beta of 0.98. The company’s 50 day moving average price is $122.39 and its two-hundred day moving average price is $127.49. Zoetis Inc. has a 52 week low of $113.29 and a 52 week high of $172.23.

Zoetis (NYSE:ZTS) last announced its earnings results on Thursday, February 12th. The company reported $1.48 EPS for the quarter, topping the consensus estimate of $1.40 by $0.08. The firm had revenue of $2.39 billion for the quarter, compared to the consensus estimate of $2.36 billion. Zoetis had a net margin of 28.24% and a return on equity of 62.02%. The business’s quarterly revenue was up 3.0% on a year-over-year basis. During the same period last year, the company posted $1.40 EPS. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. On average, analysts expect that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 2nd. Shareholders of record on Monday, April 20th will be paid a $0.53 dividend. The ex-dividend date of this dividend is Monday, April 20th. This represents a $2.12 annualized dividend and a dividend yield of 1.8%. Zoetis’s dividend payout ratio (DPR) is currently 35.22%.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.